Email this article Efficacy and safety of the first made in Russia alpha, beta long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree
- Authors: Belyaeva SA1,2, Belyaeva SA3,4
-
Affiliations:
- ГУ Научный центр биомедицинских технологий РАМН
- ГКБ № 23 им. "Медсантруд" Москвы
- Research Center for Biomedical technologies, Moscow
- "Medsantrud" hospital N 23, Moscow
- Issue: Vol 83, No 4 (2011)
- Pages: 52-55
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30848
- ID: 30848
Cite item
Full Text
Abstract
Aim. To study efficacy and safety of a new dose and dosage form of proxodolol - a beta-adrenoblocker with alpha1-adrenoblocking activity - in patients with moderate arterial hypertension (AH).
Material and methods. A total of 60 patients with verified diagnosis of essential AH of the second degree were randomized into two groups: group 1 (n = 40) received proxodolol, group 2 (n = 20) was given carvedilol. The trial lasted for 89 days.
Results. The trial demonstrates that proxodolol is highly effective and safe in the treatment of AH.
Conclusion. Proxodolol is effective and safe in hypertension, in a dose 120 mg its activity is the same as carvedilol in a dose 25 mg.
Material and methods. A total of 60 patients with verified diagnosis of essential AH of the second degree were randomized into two groups: group 1 (n = 40) received proxodolol, group 2 (n = 20) was given carvedilol. The trial lasted for 89 days.
Results. The trial demonstrates that proxodolol is highly effective and safe in the treatment of AH.
Conclusion. Proxodolol is effective and safe in hypertension, in a dose 120 mg its activity is the same as carvedilol in a dose 25 mg.
Keywords
About the authors
S A Belyaeva
ГУ Научный центр биомедицинских технологий РАМН; ГКБ № 23 им. "Медсантруд" Москвы
Email: Belyaeva.solvay@rambler.ru
врач 10-го терапевтического отд-ния ГКБ № 23 им. "Медсантруд"; ГУ Научный центр биомедицинских технологий РАМН; ГКБ № 23 им. "Медсантруд" Москвы
S A Belyaeva
Research Center for Biomedical technologies, Moscow;"Medsantrud" hospital N 23, MoscowResearch Center for Biomedical technologies, Moscow;"Medsantrud" hospital N 23, Moscow
References
- Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual date for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1993.
- Lopes A. D., Mathers C. D., Ezzati M. et al. Global and regional burden of disease and risk factor, 2001: systemic analysis of population health data. Lancet 2006; 367: 1747-1757.
- Danhlof B., Lindhalm L. H., Hannson L. et al. STOP-Hypertension 2: A prospective intervention trial of "newer" versus "older" treatment in old patients with hypertension. Blood Pressure 1993; 2: 136-141.
- Poole-Wilson P. et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur. J. Heart Fail. 2002; 4: 321-329.
